Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique

References

• AGUADO, M. T., and LAMBERT, P. H., 1992, Controlled-release vaccines—biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology, 184, 113–125.
   PubMedGoogle Scholar
• ALONSO, M. J., GUPTA, R. K., MIN, C., SIBER, G. R., and LANGER, R., 1994, Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine, 12, 299–306.
   PubMedGoogle Scholar
• BABA, E., NAKAMURA, M., TANAKA, Y., KUROKI, M., ITOYAMA, Y., NAKANO, S., and NIHO, Y., 1993, Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine. Journal of Immunology, 151, 1013–1024.
   PubMedGoogle Scholar
• BAIN, D. F., MUNDAY, D. L., and SMITH, A., 1999, Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(3L-lactide). Journal of Microencapsulation, 16, 369–385.
   PubMed Web of Science ®Google Scholar
• BLANCO-PRIETO, M. J., FATTAL, E., PUISIEUX, F., and COUVREUR, P., 1998, New approaches for encapsulation of peptides into poly(lactic/glycolic acid) microspheres. Annales Pharmaceutiques Francaises, 56, 256–263.
   Google Scholar
• CLELAND, J. L., and JONES, A. J., 1996, Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable micro-spheres. Pharmaceutical Research, 13, 1464–1475.
   PubMedGoogle Scholar
• ELDRIDGE, J. H., HAMMOND, C. J., MEULBROEK, J. A., STAAS, J. K., GILLEY, R. M., and TICE, T. R., 1990, Controlled vaccine release in the gut-associated lymphoid tissues. 1. Orally administered biodegradable microspheres target the Peyer-s patches. Journal of Controlled Release, 11, 2105–2114.
   Google Scholar
• ELDRIDGE, J. H., MEULBROEK, J. A., STAAS, J. K., TICE, T. R., and GILLEY, R. M., 1989, Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Advances in Experimental Medicine and Biology, 251, 191–202.
   PubMedGoogle Scholar
• ELDRIDGE, J. H., STAAS, J. K., MEULBROEK, J. A., MCGHEE, J. R., TICE, T. R., and GILLEY, R. M., 1991b, Biodegradable microspheres as a vaccine delivery system. Molecular Immunology, 28, 287–294.
   PubMedGoogle Scholar
• ELDRIDGE, J. H., STAAS, J. K., MEULBROEK, J. A., TICE, T. R., and GILLEY, R. M., 1991a, Biodegradable and biocompatible poly(m—lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infection and Immunity, 59, 2978–2986.
   PubMedGoogle Scholar
• ERTL, H. C., VARGA, I., XIANG, Z. Q., KAISER, K., STEPHENS, L., and OTVOS, L. J., 1996, Poly(m—lactide-co-glycolide) microspheres as carriers for peptide vaccines. Vaccine, 14, 879–885.
   PubMedGoogle Scholar
• Ho, P. C., MUTCH, D. A., WINKEL, K. D., SAUL, A. J., JoNEs, G. L., DORAN, T. J., and RZEPCZYK, C. M., 1990, Identification of two promiscuous T cell epitopes from tetanus toxin. European Journal of Immunology, 20, 477–483.
   PubMedGoogle Scholar
• KAUMAYA, P. T., KOBS-CONRAD, S., So, Y. H., LEE, H., VANBUSKIRK, A. M., FENG, N., SHERIDAN, J. F., and STEVENS, V., 1993, Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Journal of Molecular Recognition, 6, 81–94.
   Google Scholar
• KOBS-CONRAD, S., LEE, H., DIGEORGE, A. M., and KAUMAYA, P. T. P., 1993, Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4). Journal of Biological Chemistry, 268, 25285–25295.
   Google Scholar
• LAIRMORE, M. D., DIGEORGE, A. M., CONRAD, S. F., TREVINO, A. V., LAL, R. B., and KAUMAYA, P. T., 1995, Human T-Iymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immuno-genicity and overcome genetic restriction. Journal of Virology, 69, 6077–6089.
   PubMedGoogle Scholar
• NIXON, D. F., HIOE, C., CIIEN, P. D., BIAN, Z., KUEBLER, P., Li, M. L., Qiu, H., Li, X. M., SINGH, M., RICHARDSON, J., McGEE, P., ZAMB, T., KOFF, W., WANG, C. Y., and O'HAGAN, D., 1996, Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 14, 1523–1530.
   Google Scholar
• OGAWA, Y., YAMAMOTO, M., OKADA, H., YASHIKI, T., and SHIMAMOTO, T., 1988a, A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chemical and Pharmaceutical Bulletin, 36, 1095–1103.
   PubMed Web of Science ®Google Scholar
• OGAWA, Y., YAMAMOTO, M., TAKADA, S., OKADA, H., and SHIMAMOTO, T., 1988b, Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/ glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. Chemical and Pharmaceutical Bulletin, 36, 1502–1507.
   PubMed Web of Science ®Google Scholar
• O'HAGAN, D. T., JEFFERY, H., ROBERTS, M. J., McGEE, J. P., and DAVIS, S. S., 1991b, Controlled release microparticles for vaccine development. Vaccine, 9, 768–771.
   Google Scholar
• O'HAGAN, D. T., MCGEE, J. P., HOLMGREN, J., MOWAT, A. M., DONACHIE, A. M., MILLS, K. H., GAISFORD, W., RAHMAN, D., and CHALLACOMBE, S. J., 1993, Biodegradable microparticles for oral immunization. Vaccine, 11, 149–154.
   Google Scholar
• O'HAGAN, D. T., RAHMAN, D., McGEE, J. P., JEFFERY, H., DAVIES, M. C., WILLIAMS, P., DAVIS, S. S., and CHALLACOMBE, S. J., 1991a, Biodegradable microparticles as controlled release antigen delivery systems. Immunology, 73, 239–242.
   Google Scholar
• PALKER, T. J., TANNER, M. E., SCEARCE, R. M., STREILEIN, R. D., CLARK, M. E., and HAYNES, B. F., 1989, Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. Journal of Immunology, 142, 971–978.
   PubMedGoogle Scholar
• PANINA-BORDIGNON, P., TAN, A., TERMIJTELEN, A., DEMOTZ, S., CORRADIN, G., and LANZAVECCHIA, A., 1989, Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. European Journal of Immunology, 19, 2237–2242.
   PubMedGoogle Scholar
• PARTIDOS, C. D., and STEWARD, M. W., 1990, Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. Journal of General Virology, 17, 2099–2105.
   Google Scholar
• PERUMAL, D., DANGOR, C. M., ALcocK, R. S., HURBANS, N., and MOOPANAR, K. R., 1999, Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres. Journal of Microencapsulation, 16, 475–487.
   PubMedGoogle Scholar
• PIQUE, C., CONNAN, F., LEVILAIN, J. P., CHOPPIN, J., and DOKHELAR, M. C., 1996, Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response. Journal of Virology, 70, 4919–4926.
   PubMedGoogle Scholar
• Rosimo, V., DEYME, M., BENOIT, J. P., and MADELMONT, G., 1998, Physical aging of progesterone-loaded poly(D,L,-lactide-co-glycolide) microspheres. Pharmaceutical Research, 15, 794–798.
   PubMedGoogle Scholar
• ROY, S., SCHERER, M. T., BRINER, T. J., SMITH, J. A., and GEFTER, M. L., 1989, Murine MHC polymorphism and T cell specificities. Science, 244, 572–575.
   PubMedGoogle Scholar
• SAH, H., 1999, Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. Journal of Controlled Release, 58, 143–151.
   PubMedGoogle Scholar
• SCHWENDEMAN, S. P., CARDAMONE, M., BRANDON, M. R., KLIBANOV, A., and LANGER, R., 1996, Stability of proteins and their delivery from biodegradable polymer microspheres. In Microparticulate systems for the delivery of proteins and vaccines, edited by S. Cohen and H. Bernstein (New York: Marcel Dekker), pp. 1–50.
   Google Scholar
• SCHWENDEMAN, S. P., COSTANTINO, H. R., GUPTA, R. K., and LANGER, R., 1997, Progress and challenges for peptide, protein, and vaccine delivery from implantable polymeric systems. In Controlled Drug Delivery: Challenges and Strategies, edited by K. Park (Washington, DC: The American Chemical Society), pp. 229–267.
   Google Scholar
• SHENDEROVA, A., BURKE, T. G., and SCHWENDEMAN, S. P., 1999, The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharmaceutical Research, 16, 241–248.
   PubMedGoogle Scholar
• SINGH, M., SINGH, A., and TALWAR, G. P., 1991, Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) micro capsules. Pharmaceutical Research, 8, 958–961.
   PubMedGoogle Scholar
• SINIGAGLIA, F., GUTTINGER, M., KILGUS, J., DORAN, D. M., MATILE, H., ETLINGER, H., TRZECIAK, A., GILLESSEN, D., and PINK, J. R., 1988, A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature, 336, 778–780.
   PubMedGoogle Scholar
• SUGIYAMA, T., KUMAGAI, S., NISIIIDA, T., USHIJIMA, K., MATSUO, T., YAKUSHIJI, M., HYON, S. H., and IKADA, Y., 1998, Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Research, 18, 2837–2842.
   PubMedGoogle Scholar
• UCHIDA, T., GOTO, S., and FOSTER, T., 1994, Particle size studies for subcitaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulations. Journal of Pharmacy and Pharmacology, 47, 556–560.
   Google Scholar
• URATA, T., ARIMORI, K., and NAKANO, H., 1999, Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. Journal of Controlled Release, 58, 133–141.
   PubMedGoogle Scholar
• WANG, J., and SCIIWENDEMAN, S. P., 1999, Mechanisms of solvent evaporation encapsulation processes: prediction of solvent evaporation rate. Journal of Pharmaceutical Sciences, 88, 1090–1099.
   PubMedGoogle Scholar
• Zuu, G., MALLERY, S. R., and SCIIWENDEMAN, S. P., 2000, Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide). Nature Biotechnology, 18, 52–57.
   PubMedGoogle Scholar